CD274 and non-small cell lung carcinoma: According to NCCN guidelines V1.2023 NSCLC, one of the recommended first-line therapy for advanced adenocarcinoma, large cell, and NSCLC not otherwise specified (NOS) patients is carboplatin + paclitaxel + bevacizumab + atezolizumab (ABCP) (39), with PD-L1 expression whether ≥50% or ranges between 1%-49%.